Abstract
Purpose: The purpose of this study was to evaluate the efficacy of a combined application of iliac crest autograft (ICAG) and human recombinant osteogenic protein 1 (BMP-7) for the treatment of non-unions of long bones fractures (LBF).
Patients and Methods: At both institutions we have prospectively and retrospectively collected and analysed data of patients admitted between October 2001 and August 2004 with a LBF nonunion (humerus, femur, tibia) and whose nonunion sites have been grafted with a combination of BMP7 and ICAG. All the records of the patients’ initial injury incident and treatment course, together with following operative interventions till and after the BMP7 application, and their follow up till final union have been analysed. Painless full weight bearing or use of the upper limp in the case of humerus (clinical union), and presence of bridging callous of two cortices visible on two x-ray views (radiological union). Chi square test was used to analyse the results.
Results: Forty-nine patients (31 males) with a mean age of 43 years (18–79) with LBF non-unions were identified. The mean follow-up was 21.4 months (range 12–65). 7 were humerus, 13 femurs, and 29 tibias. Eleven cases were open (3 grade II, and 8 grade IIIa-b). All non-unions were atrophic, and 8 were initially associated with bone loss. The mean number of operations performed prior to the combined ICAG and BMP7 application was 2.5 (0–6), including ICAG in 12 cases and bone marrow injection in 1 case. All but one of the fractures have united. Clinical and Radiological union occurred within a mean time of 4.4 (3–12) months and 5.4 (4–16) months respectively. One patient, with an infected tibial non-union following an open fracture, ultimately underwent a below knee amputation, secondary to recurrence of deep sepsis. The only patient whose (tibial) fracture has not still united is currently on an Ilizarov frame and slow progression has been reported following a recent CT. No complications or adverse effects from the use of BMP-7 were encountered.
Conclusion: BMP-7 was used as a bone stimulating agent combined with conventional iliac crest bone grafting with a success rate of 98% in this series of patients with LBF non-unions. This study supports the view that this combination of BMP-7 is safe and a power adjunct to be considered in the surgeon’s armamentarium for the management of such difficult cases.
Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org
